

**AMENDMENT**

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

**IN THE CLAIMS**

Please amend the allowed claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Claims 1-15 (canceled)

~~1~~ ~~16~~. (previously presented) A liquid polymeric composition for controlled release of eprinomectin consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and
- (c) at least one lipophilic solvent or a mixture of hydrophilic and lipophilic solvents, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 5:95.

~~2~~ ~~17~~. (previously presented) The composition of claim ~~16~~ wherein the lipophilic solvent is triacetin.

~~12~~ ~~18~~. (previously presented) The composition of claim ~~16~~ wherein the hydrophilic solvent is N-methyl pyrrolidone.

~~3~~ ~~19~~. (previously presented) The composition of claim ~~17~~ wherein the hydrophilic solvent is N-methyl pyrrolidone.

~~8~~ ~~20~~. (previously presented) The composition of claim ~~17~~ consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less

and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

<sup>4</sup>  
~~21.~~ (c) triacetin.  
<sup>3</sup>  
~~(currently amended) The composition of claim 19~~ consisting essentially of:

(a) 1 to 10% of eprinomectin;

(b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

<sup>1</sup>  
~~(c) triacetin~~ N-methyl pyrrolidone and N-methyl pyrrolidone triacetin,  
wherein the volume ratio of the ~~triacetin~~ N-methyl pyrrolidone and N-methyl pyrrolidone triacetin is from about 80:20 to about 5:95.

<sup>9</sup>  
~~22.~~ (previously presented) The composition of claim ~~20~~ wherein (a) consists essentially of about 5% eprinomectin.

<sup>5</sup>  
~~23.~~ (previously presented) The composition of claim ~~21~~ wherein (a) consists essentially of about 5% eprinomectin.

<sup>10</sup>  
~~24.~~ (previously presented) The composition of claim ~~22~~ wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

<sup>6</sup>  
~~25.~~ (previously presented) The composition of claim ~~23~~ wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

<sup>11</sup>  
~~26.~~ (previously presented) The composition of claim ~~24~~ wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

<sup>7</sup>  
~~27.~~ (previously presented) The composition of claim ~~25~~ wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

<sup>13</sup>  
~~28.~~ (previously presented) A method for the controlled release of eprinomectin in a mammal which comprises injecting said mammal with the composition of any one of claims ~~16-27.~~  
<sup>1-12</sup>

<sup>14</sup>  
~~29.~~ (previously presented) The method of claim ~~28~~ wherein the mammal is a bovine.  
<sup>13</sup>

*G<sup>1</sup> contd*

<sup>15</sup>  
~~30.~~ (previously presented) The method of claim <sup>13</sup>~~28~~ wherein the mammal is an  
ovine.

<sup>16</sup>  
~~31.~~ (previously presented) The method of claim <sup>13</sup>~~28~~ wherein the mammal is a  
canine.--

---